MS HB1387

Allows pharmacists to substitute FDA-approved interchangeable biosimilar products for prescribed biological products under specified conditions.

Requires the prescriber has not expressly prohibited substitution in writing, verbally, or electronically.

Mandates patient notification and consent before substitution occurs.

Requires pharmacist to notify prescriber of substitution within five business days by facsimile, telephone, voice mail, email, or electronic means.

Directs State Board of Pharmacy to maintain a public website list of biosimilar products determined to be interchangeable by the FDA; takes effect July 1, 2013.